2005
DOI: 10.1016/j.jhep.2005.01.028
|View full text |Cite
|
Sign up to set email alerts
|

Generation of a monoclonal human single chain antibody fragment to hepatic stellate cells – a potential mechanism for targeting liver anti-fibrotic therapeutics

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
33
0

Year Published

2008
2008
2021
2021

Publication Types

Select...
3
3

Relationship

2
4

Authors

Journals

citations
Cited by 34 publications
(33 citation statements)
references
References 29 publications
0
33
0
Order By: Relevance
“…They have also been shown to inactivate and acquire a quiescent-like phenotype, which might help with regression of liver fibrosis [114,115]. As well, blockage of certain proteins in HSC activation pathways might prove to have therapeutic implication in human diseases [98,[116][117][118]. Mouse model studies and advanced HSC isolation techniques have contributed to the elucidation of this cell's functions.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…They have also been shown to inactivate and acquire a quiescent-like phenotype, which might help with regression of liver fibrosis [114,115]. As well, blockage of certain proteins in HSC activation pathways might prove to have therapeutic implication in human diseases [98,[116][117][118]. Mouse model studies and advanced HSC isolation techniques have contributed to the elucidation of this cell's functions.…”
Section: Discussionmentioning
confidence: 99%
“…This neural marker was present in perisinusoidal HSCs in human normal liver biopsies, and increased in pathological conditions such as chronic biliary disease and chronic hepatitis C [69,97,98].…”
Section: Syn (Synaptophysin)mentioning
confidence: 97%
“…The first approach was to exploit the fact that HMs express significantly higher levels of the protein synaptophysin on their cell membrane compared to qHSCs [36]. Phage display was used to generate a human recombinant single-chain antibody (scAb), C1-3 that binds to synaptophysin on the surface of HMs [37]. Fluorescent labeled C1-3 was shown to co-localize with α-sma+ HMs but not ED1+ macrophages or hepatocytes.…”
Section: Reduce Adverse Effectsmentioning
confidence: 99%
“…The polyhistidine tagged recombinant scAbs -C1-3 (to synaptophysin) and CSBD9 (to microcystin-LR [22] and used as a control in these studies) were expressed in Escherichia coli and purified by nickel chromatography and gel filtration essentially as previously described [20,22]. Endotoxin was removed from preparations using Q Maxi H columns (Sartorius Vivascience, Epsom, UK) and all preparations were tested (<0.2 EU/ml) by Lonza Biologics (Slough, UK) prior to use in vivo.…”
Section: Recombinant Scab Expression and Conjugationmentioning
confidence: 99%
“…Synaptophysin's external cellular location and cycling to intracellular location(s) make it a potential site for targeting liver myofibroblasts with therapeutics. Recombinant human monoclonal single chain antibodies (scAbs) were therefore generated to a conserved peptide sequence present in an extracellular domain of synaptophysin [20].…”
Section: Introductionmentioning
confidence: 99%